LB Pharmaceuticals Inc

US$42.01As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:LBRXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (38.80%)
Biotechnology
Beta (5Y) —
PE TTM —
TSR TTM 160.45%
Mkt cap US$1.355B
ROIC (25.70%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$53
25.83%
489.95%
Hold 7|0|1|12|4
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.78
0.82
0.81
0.83
14.99%
21.51%
10.03%
7.61%
Revenue$M
150.6
147.3
154.1
150.9
9.01%
2.21%
3.63%
(0.80%)
Peers (US$1.355B)
Cap (US$)
PE
1.389B
6.637x
1.358B
7.510x
Capital
TTM
5Y
10Y
Leveragex
0.081
0.050
0.058
EBIT/Intx
2.140
0.498
0.558
Own earn%
(215.48)
(281.86)
(214.78)
Sh yield%
27.93
10.47
10.84
Owners
Insiders/Inst%
0.33
45.70
Short interest%
5.40
SBC / revenue%
0.22
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
18
Op margin range%
0–3
$1 testx
0.0
Incr. ROIC%
4